BRIEF—Relief Therapeutics appoints David McCullough as Head of US Market Access

The Swiss biopharmaceutical company Relief Therapeutics has announced the appointment of David McCullough as senior director and the newly created position - head of US market access.

Mr McCullough will direct Relief’s market access strategy and operations to ensure timely and effective access to Relief’s products for patients in the USA.

Prior to joining Relief, Mr McCullough served as national account director at Mirum Pharmaceuticals where he was responsible for building out the company’s Medicaid launch strategy and supporting the expansion of key market access policies. Previously, he held positions at Novartis Gene Therapies, Spark Therapeutics and Shire.

Anthony Kim, senior vice president and head of US commercial operations at Relief, said: "As we continue to grow, David’s more than 20 years of extensive commercial experience working with payors, physicians and specialty pharmacies to help ensure access for patients and their families, will be invaluable. We look forward to leveraging his broad knowledge of market access in preparation for our October 2022 US launch of PKU GOLIKE."